Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver-Targeted therapy plus immunotherapy shows promise for advanced melanoma

NCT ID NCT07281924

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 7 times

Summary

This study tests whether combining a liver-directed chemotherapy (HEPZATO KIT) with an immunotherapy drug (Opdualag) is safe and effective for people with metastatic melanoma that has spread to the liver. About 15 participants who have not received prior systemic treatment will receive the combination. The goal is to see if this approach can shrink tumors better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Melphalan (HEPZATO KIT) and nivolumab/relatlimab (Opdualag)
What this could lead to
If successful, this combination could offer a new treatment option for people with melanoma that has spread to the liver, potentially improving tumor shrinkage and outcomes.
What could go wrong
This is an early-phase trial with only 15 participants, so results may not apply broadly. The combination may cause serious side effects, and it is not yet known if it works better than existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER METASTASES METASTATIC MELANOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • UW Hospital and Clinics

    RECRUITING

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.